Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)
China · Delayed Price · Currency is CNY 19.57
+0.10 (0.51%)
Nov 3, 2025, 2:45 PM CST
SHE:002755 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 256.59 | 160.29 | -148.53 | -225.83 | 379.91 | 721.63 | Upgrade |
Depreciation & Amortization | 78.41 | 78.41 | 84.7 | 92.19 | 94.51 | 92.62 | Upgrade |
Other Amortization | 13.77 | 13.77 | 4.85 | 5.67 | 4.15 | 1.95 | Upgrade |
Loss (Gain) From Sale of Assets | 0.03 | 0.03 | -0.03 | -0.21 | -0.3 | 0.02 | Upgrade |
Asset Writedown & Restructuring Costs | 3.06 | 3.06 | 5.7 | 1.09 | 0.86 | 0.26 | Upgrade |
Loss (Gain) From Sale of Investments | -27.32 | -27.32 | -26.89 | -29.72 | -20.68 | -7.28 | Upgrade |
Provision & Write-off of Bad Debts | -0.16 | -0.16 | -4.48 | -7.02 | -4.51 | -8.38 | Upgrade |
Other Operating Activities | 31.88 | -26.11 | -52.51 | -13.44 | 4.75 | 8.51 | Upgrade |
Change in Accounts Receivable | -154.15 | -154.15 | 53.45 | 262.97 | 363.45 | 110.98 | Upgrade |
Change in Inventory | -31.38 | -31.38 | -26.41 | -1.79 | 26.89 | 57.82 | Upgrade |
Change in Accounts Payable | 395.15 | 395.15 | 93.18 | -133.44 | -281.03 | -393.7 | Upgrade |
Change in Other Net Operating Assets | -8.32 | -8.32 | -7.34 | -3.61 | 1.92 | 1.83 | Upgrade |
Operating Cash Flow | 565.64 | 411.36 | -26.57 | -52.81 | 567.71 | 580.38 | Upgrade |
Operating Cash Flow Growth | 31.43% | - | - | - | -2.18% | 8.56% | Upgrade |
Capital Expenditures | -304.34 | -230.42 | -129.32 | -150.45 | -133.76 | -199.68 | Upgrade |
Sale of Property, Plant & Equipment | 0.01 | 0.66 | 0.59 | 0.88 | 0.94 | 0.01 | Upgrade |
Divestitures | 0.52 | - | - | - | - | - | Upgrade |
Investment in Securities | -36.53 | 29.47 | 115 | -315 | -438 | -18 | Upgrade |
Other Investing Activities | 29.85 | 27.05 | 25.29 | 25.65 | 7.79 | 1.93 | Upgrade |
Investing Cash Flow | -310.49 | -173.24 | 11.56 | -438.92 | -563.02 | -215.74 | Upgrade |
Short-Term Debt Issued | - | 101.62 | 154.72 | 45 | - | 22.44 | Upgrade |
Total Debt Issued | 108.62 | 101.62 | 154.72 | 45 | - | 22.44 | Upgrade |
Short-Term Debt Repaid | - | -54 | -65.72 | - | -20 | - | Upgrade |
Long-Term Debt Repaid | - | -3.34 | -3.08 | -2.91 | -2.76 | - | Upgrade |
Total Debt Repaid | -35.34 | -57.34 | -68.8 | -2.91 | -22.76 | - | Upgrade |
Net Debt Issued (Repaid) | 73.27 | 44.27 | 85.92 | 42.09 | -22.76 | 22.44 | Upgrade |
Issuance of Common Stock | 30 | - | 206.38 | 127.02 | 0.38 | - | Upgrade |
Repurchase of Common Stock | - | - | - | - | -1.6 | -0.07 | Upgrade |
Common Dividends Paid | -111.92 | -1.16 | -1.12 | -93.19 | -185.76 | -205.19 | Upgrade |
Other Financing Activities | 0.31 | - | - | - | - | - | Upgrade |
Financing Cash Flow | -8.34 | 43.11 | 291.17 | 75.91 | -209.74 | -182.82 | Upgrade |
Foreign Exchange Rate Adjustments | -2.31 | 3.09 | -1.2 | 15.6 | -0.02 | -0.06 | Upgrade |
Net Cash Flow | 244.5 | 284.32 | 274.97 | -400.22 | -205.07 | 181.76 | Upgrade |
Free Cash Flow | 261.3 | 180.94 | -155.89 | -203.27 | 433.95 | 380.7 | Upgrade |
Free Cash Flow Growth | -5.60% | - | - | - | 13.99% | 4.13% | Upgrade |
Free Cash Flow Margin | 14.30% | 10.18% | -10.80% | -10.85% | 13.97% | 10.06% | Upgrade |
Free Cash Flow Per Share | 0.27 | 0.19 | -0.17 | -0.22 | 0.47 | 0.41 | Upgrade |
Cash Interest Paid | - | - | - | - | 0.27 | - | Upgrade |
Cash Income Tax Paid | 224.5 | 204 | 136.72 | 208.09 | 433.1 | 499.23 | Upgrade |
Levered Free Cash Flow | 304.42 | 311.79 | -83.12 | -101.11 | 263.79 | 112.12 | Upgrade |
Unlevered Free Cash Flow | 305.74 | 313.44 | -81.37 | -99.38 | 266.28 | 113.96 | Upgrade |
Change in Working Capital | 209.37 | 209.37 | 110.63 | 124.45 | 109.03 | -228.91 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.